Striverdi Respimat efficacy in Phase III COPD trials

Data from the Phase III clinical program show the use of Striverdi Respimat (olodaterol), from Boehringer, provided improvements in lung function in patients with moderate to very severe Chronic Obstructive Pulmonary Disease (COPD). The data are from two sets of 48-week pivotal studies evaluating the long-term efficacy and safety of once-daily olodaterol in 5 and 10 mcg doses, delivered via the Respimat inhaler, as well as two sets of 6-week studies investigating olodaterol's 24-hour bronchodilation profile. Data shows the drug provided statistically significant improvements in lung function, as measured by FEV1, versus placebo plus usual care in patients with moderate to very severe COPD. It also provided comparable improvements in lung function compared to 12 mcg formoterol twice daily in these COPD patients.

Olodaterol 5 mcg was shown to provide significant improvement in lung function within five minutes following the first dose. In addition, COPD patients had less need for both day- and night-time rescue medication when using both doses of olodaterol. In the 6-week studies, there was no significant difference in adverse events between the olodaterol treatment arm and the placebo arm. Results were presented at the European Respiratory Society Annual Congress.